Skip to main content
OpenTrials
Completed

NCT Number: NCT01494441

Pilot Study of rhBMP/BCP With or Without the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Degenerative Disc Disease

The purpose of this pilot clinical trial is to evaluate both device designs (rhBMP-2/BCP and rhBMP-2/BCP/TSRH® spinal System) as methods of facilitating spinal fusion as compared to instrumented fusion with autograft in patients with symptomatic degenerative disc disease.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Has degenerative disc diseases noted by back pain of discogenic origin,with or without leg pain, with degeneration of the disc confirmed by patient history ( e.g., pain [leg, back, or symptoms in the sciatic nerve distribution] function deficit and/or neurological deficit) and radiographic studies ( e.g., CT, MRl, X-Ray,etc.) to include one or more of the following:
  • instability (defined as angular motion > 5° and/or translation > 4 mm, based on Flex/Ext radiographs);
  • osteophyte formation;
  • decreased disc height;
  • thickening of ligamentous tissue;
  • disc degeneration or herniation; and/or
  • facet joint degeneration.
  • Has preoperative Oswestry score > 30.
  • Has no greater than Grade 1 spondylolisthesis utilizing Meyerding's Classification (Meyerding HW,1932.).
  • Requires fusion of a single level disc space from L1 to S1.
  • Is at least 18 years of age, inclusive, at the time of surgery.
  • Has not responded to non-operative treatment ( e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of at least 6 months.
  • If female of child-bearing potential, who is not pregnant or nursing, and who agrees to use adequate contraception for 16 weeks following surgery.
  • Is willing and able to comply with the study plan and sign the Patient Informed Consent Form.

Exclusion criteria

  • Has primary diagnosis of a spinal disorder other than degenerative disc disease with Grade1 or less spondylolisthesis at the involved level.
  • Had previous spinal fusion surgical procedure at the involved level.
  • Require spinal fusion at more than one lumbar level.
  • Has a condition which requires postoperative medications that interfere with fusion, such as steroids.
  • Has been previously diagnosed with osteopenia, osteoporosis, or osteomalacia to a degree that spinal instrumentation would be contraindicated.
  • Has presence of active malignancy.
  • Has overt or active bacterial infection, either local or systemic.
  • Is grossly obese, i.e., weight > 40% over ideal for their age and height.
  • Has fever ( temperature >101°F oral) at the time of surgery.
  • Has a documented titanium alloy allergy or intolerance.
  • Is mentally incompetent. If questionable, obtain psychiatric consult.
  • Has a Waddell Signs of Inorganic Behavior score of 3 or greater.
  • Is a prisoner.
  • Is an alcohol and/or drug abuser as defined by currently undergoing treatment for alcohol and/or drug usage.
  • Is a tobacco user at the time of surgery.
  • Has received drugs which may interfere with bone metabolism within two weeks prior to the planned date of spinal fusion surgery (e.g., NSAIDS, steroids or methotrexate).
  • Has a history of autoimmune disease (Systemic Lupus Erythematosus or Dermatomyositis).
  • Has a history of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or gamma globulins).
  • Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP-2/BCP implantation.
  • Has received any previous exposure to any/all BMPs of either human or animal extraction.
  • Has a history of severe allergy (anaphylaxis).
  • Has history of endocrine or metabolic disorder known to affect osteogenesis (e.g., Paget's disease, renal osteodystrophy, Ehlers- Danlos syndrome, or osteogenesis imperfecta).

Treatment and study plan

rhBMP-2/BCP

Procedure

The rhBMP-2/BCP device component consists of recombinant human Bone Morphogenetic Protein-2 ( rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.

Other names: recombinant human Bone Morphogenetic Protein-2, biphasic calcium phosphate

rhBMP-2/BCP/TSRH® Spinal System

Device

rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, the TSRH® Spinal System.

Other names: recombinant human Bone Morphogenetic Protein-2, biphasic calcium phosphate

Autograft/TSRH® Spinal System

Device

The control device will be autogenous bone from the iliac crest of the patient used in conjunction with the TSRH® spinal System.

Other names: Autograft

Primary outcomes

  1. Fusion

    Time frame: 24 month

    Fusion is defined as:

    • Evidence of bridging trabecular bone.
    • No evidence of motion as defined by: a. No more than 3mm difference in translation on the lateral flexion/extension radiographs determined by superimposing the two views, one upon the other; b. Less than 5° difference in angular motion between flexion and extension as seen on the lateral flexion/extension radiographs;
    • Absence of radiolucent lines completely through the fusion mass.
  2. Pain/Disability Status

    Time frame: 24 month

    The self-administered Oswestry Low Back pain Disability Questionnaire will be used. Success for each individual patient will be defined as pain/disability improvement postoperatively according to the following definition: Preoperative Score - Postoperative Score >= 15

Secondary outcomes

  1. Neurological Status Success

    Time frame: 24 month

    Neurological status will be assessed preoperatively and postoperatively using a comprehensive neurological status scale. Neurological status is based on four types of measurements (sections): motor, sensory, reflexes and straight leg raise.

  2. Hip (Donor Site) Pain

    Time frame: 24 month

  3. General Health Status (SF-36)

    Time frame: 24 month

  4. Pain Status (back pain, leg pain)

    Time frame: 24 month

  5. Patient Satisfaction

    Time frame: 24 month

  6. Patient Global Perceived Effect

    Time frame: 24 month

  7. Overall Success

    Time frame: 24 month

Sponsors and collaborators

Lead sponsor

Medtronic Spinal and Biologics

Industry

Registry information

Official study title

A Pilot Study of Recombinant Human Bone Morphogenetic Protein-2 and Biphasic Calcium Phosphate With or Without the TSRH® Spinal System for Posterolateral Lumbar Fusion in Patients With Symptomatic Degenerative Disc Disease

Important dates

Study start
1999
Primary completion
2003
Study completion
2003
First posted
Dec 19, 2011
Registry last updated
May 17, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.